Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
New view at FDA gets treatments to patients faster
Changes in oncologists' treatment expectations, greater influence and advocacy from patients and scientific discoveries fundamentally changed how the FDA reviews cancer drugs, writes Dr. Patricia Keegan, director of the Division of Oncology Products 2 in the agency's Office of Hematology and Oncology Products. Doctors care less about whether a drug shrinks a tumor than its ability to extend life or prevent metastasis, and independent experts urged the FDA to approve drugs sooner, based on a single efficacy study, she writes. The agency now approves cancer drugs faster so patients can benefit sooner, as exemplified in the area of drugs to treat metastatic cancer, Keegan writes.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .